Department of Surgery, University of Hong Kong, Pokfulam, Hong Kong, China.
J Clin Invest. 2011 Mar;121(3):880-92. doi: 10.1172/JCI40433.
Metastasis is a major cause of mortality in cancer patients. However, the mechanisms governing the metastatic process remain elusive, and few accurate biomarkers exist for predicting whether metastasis will occur, something that would be invaluable for guiding therapy. We report here that the carboxypeptidase E gene (CPE) is alternatively spliced in human tumors to yield an N-terminal truncated protein (CPE-ΔN) that drives metastasis. mRNA encoding CPE-ΔN was found to be elevated in human metastatic colon, breast, and hepatocellular carcinoma (HCC) cell lines. In HCC cells, cytosolic CPE-ΔN was translocated to the nucleus and interacted with histone deacetylase 1/2 to upregulate expression of the gene encoding neural precursor cell expressed, developmentally downregulated gene 9 (Nedd9)--which has been shown to promote melanoma metastasis. Nedd9 upregulation resulted in enhanced in vitro proliferation and invasion. Quantification of mRNA encoding CPE-ΔN in HCC patient samples predicted intrahepatic metastasis with high sensitivity and specificity, independent of cancer stage. Similarly, high CPE-ΔN mRNA copy numbers in resected pheochromocytomas/paragangliomas (PHEOs/PGLs), rare neuroendocrine tumors, accurately predicted future metastasis or recurrence. Thus, CPE-ΔN induces tumor metastasis and should be investigated as a potentially powerful biomarker for predicting future metastasis and recurrence in HCC and PHEO/PGL patients.
转移是癌症患者死亡的主要原因。然而,控制转移过程的机制仍然难以捉摸,并且几乎没有准确的生物标志物可用于预测转移是否会发生,这对于指导治疗将是非常宝贵的。我们在这里报告羧肽酶 E 基因 (CPE) 在人类肿瘤中发生选择性剪接,产生一种驱动转移的 N 端截断蛋白 (CPE-ΔN)。在人转移性结肠、乳腺和肝细胞癌 (HCC) 细胞系中发现编码 CPE-ΔN 的 mRNA 升高。在 HCC 细胞中,细胞质 CPE-ΔN 易位到细胞核,并与组蛋白去乙酰化酶 1/2 相互作用,上调编码神经前体细胞表达、发育下调基因 9 (Nedd9) 的基因表达——已显示其促进黑色素瘤转移。Nedd9 的上调导致体外增殖和侵袭增强。在 HCC 患者样本中对 CPE-ΔN mRNA 的定量检测具有高灵敏度和特异性,独立于癌症分期预测肝内转移。同样,在罕见的神经内分泌肿瘤——已切除的嗜铬细胞瘤/副神经节瘤 (PHEO/PGL) 中,CPE-ΔN mRNA 拷贝数高,准确预测了未来的转移或复发。因此,CPE-ΔN 诱导肿瘤转移,应作为预测 HCC 和 PHEO/PGL 患者未来转移和复发的潜在强大生物标志物进行研究。